Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class i antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia

Circulation: Arrhythmia and Electrophysiology

Volumn 4, Issue 2, 2011, Pages 128-135

  Hwang, Hyun Seok ^a   Hasdemir, Can ^b   Laver, Derek ^d   Mehra, Divya ^d   Turhan, Kutsal ^c   Faggioni, Michela ^a   Yin, Huiyong ^a   Knollmann, Björn C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Cardiology ^*  (United States)

^c EGE UNIVERSITY   (Turkey)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Catecholaminergic polymorphic ventricular tachycardia; Class I antiarrhythmic drugs; Disopyramide; Flecainide; Lidocaine; Mexiletine; Procainamide; Propafenone; Quinidine; Ranolazine; RyR2; Tetrodotoxin

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM ION; DISOPYRAMIDE; FLECAINIDE; LIDOCAINE; MEXILETINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RYANODINE RECEPTOR 2; SODIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALSEQUESTRIN; CASQ2 PROTEIN, MOUSE; RYANODINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CASE REPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENANTIOMER; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; LIPID BILAYER; MOUSE; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; RECEPTOR BLOCKING; ADULT; ANALYSIS OF VARIANCE; ANIMAL; CARDIOVERSION; CHANNEL GATING; DEFIBRILLATOR; DISEASE MODEL; DOSE RESPONSE; ELECTROCARDIOGRAPHY; GENETICS; HEART VENTRICLE TACHYCARDIA; INSTRUMENTATION; MALE; METABOLISM; MISSENSE MUTATION; MOUSE MUTANT; PATHOPHYSIOLOGY; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; CALSEQUESTRIN; DEFIBRILLATORS, IMPLANTABLE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FLECAINIDE; HUMANS; ION CHANNEL GATING; LIDOCAINE; MALE; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; MYOCYTES, CARDIAC; PROCAINAMIDE; PROPAFENONE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SODIUM CHANNEL BLOCKERS; TACHYCARDIA, VENTRICULAR; TIME FACTORS; YOUNG ADULT;

EID: 79959193265     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.110.959916     Document Type: Article

References (41)

1. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Cate-cholaminergic polymorphic ventricular tachycardia in children: a 7-year follow-up of 21 patients. Circulation. 1995;91:1512-1519.
2. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69-74. (Pubitemid 34747444)
3. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, Mannens MM, Wilde AA, Guicheney P. Absence of calse-questrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2002;91:e21-e26.
4. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69: 1378-1384. (Pubitemid 33124218)
5. Campbell KP, MacLennan DH, Jorgensen AO, Mintzer MC. Purification and characterization of calsequestrin from canine cardiac sarcoplasmic reticulum and identification of the 53,000 Dalton glycoprotein. J Biol Chem. 1983;258:1197-1204.
6. Knollmann BC, Chopra N, Hlaing T, Akin B, Yang T, Ettensohn K, Knollmann BE, Horton KD, Weissman NJ, Holinstat I, Zhang W, Roden DM, Jones LR, Franzini-Armstrong C, Pfeifer K. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest. 2006;116:2510-2520. (Pubitemid 44330150)
7. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res. 2006;99:292-298. (Pubitemid 44174937)
8. Liu N, Rizzi N, Boveri L, Priori SG. Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice. J Mol Cell Cardiol. 2009;46:149-159.
9. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426-2434.
10. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, Dubosq-Bidot L, Sebillon P, Mannens MM, Guicheney P, Wilde AA. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet. 2005;42:863-870. (Pubitemid 41598196)
11. Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm. 2006;3: 1486-1489. (Pubitemid 44849373)
12. Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19:1319-1321.
13. Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N, Piston DW, Huke S, Knollmann BC. Flecainide inhibits arrhythmogenic Ca(2 + ) waves by open state block of ryanodine receptor Ca(2 + ) release channels and reduction of Ca(2 + ) spark mass. J Mol Cell Cardiol. 2010;48:293-301.
14. WatanabeH, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380-383.
15. Aboul-Enein HY, Bakr SA. Direct enantiomeric high performance liquid chromatographic separation of propafenone and its major metabolite in serum on a cellulose tris-3,5-dimethylphenyl carbamate chiral stationary phase. Biomed Chromatogr. 1993;7:38-40. (Pubitemid 23050573)
16. Chopra N, Laver D, Davies SS, Knollmann BC. Amitriptyline activates cardiac ryanodine channels and causes spontaneous sarcoplasmic reticulum calcium release. Mol Pharmacol. 2009;75:183-195.
17. Chopra N, Kannankeril PJ, Yang T, Hlaing T, Holinstat I, Ettensohn K, Pfeifer K, Akin B, Jones LR, Franzini-Armstrong C, Knollmann BC. Modest reductions of cardiac calsequestrin increase sarcoplasmic reticulum Ca2+ leak independent of luminal Ca2+ and trigger ventricular arrhythmias in mice. Circ Res. 2007;101:617-626. (Pubitemid 351325879)
18. Vaughan Williams EM. The relevance of cellular to clinical electrophys-iology in classifying antiarrhythmic actions. J Cardiovasc Pharmacol. 1992;20(Suppl):S1-S7.
19. Harron DW, Brogden RN. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs. 1987;34:617-647. (Pubitemid 17164011)
20. Stoschitzky K, Klein W, Stark G, Stark U, Zernig G, Graziadei I, Lindner W. Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies. Clin Pharmacol Ther. 1990;47:740-746. (Pubitemid 20207332)
21. Diaz ME, O'Neill SC, Eisner DA. Sarcoplasmic reticulum calcium content fluctuation is the key to cardiac alternans. Circ Res. 2004;94: 650-656. (Pubitemid 38387748)
22. Hasdemir C, Aydin HH, Sahin S, Wollnik B. Catecholaminergic polymorphic ventricular tachycardia caused by a novel mutation in the cardiac ryanodine receptor. Anadolu Kardiyol Derg. 2008;8:E35-E36.
23. Terentyev D, Kubalova Z, Valle G, Nori A, Vedamoorthyrao S, Terentyeva R, Viatchenko-Karpinski S, Bers DM, Williams SC, Volpe P, Gyorke S. Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: effects of CASQ2 mutations linked to sudden cardiac death. Biophys J. 2008;95:2037-2048.
24. Jiang D, Wang R, Xiao B, Kong H, Hunt DJ, Choi P, Zhang L, Chen SR. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2 + activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res. 2005;97:1173-1181.
25. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415: 198-205. (Pubitemid 34059525)
26. Venetucci LA, Trafford AW, O'Neill SC, Eisner DA. Na/Ca exchange: regulator of intracellular calcium and source of arrhythmias in the heart. Ann N Y Acad Sci. 2007;1099:315-325. (Pubitemid 47092597)
27. Marban E, Robinson SW, Wier WG. Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle. J Clin Invest. 1986;78:1185-1192. (Pubitemid 17181555)
28. Zeiler RH, Gough WB, El-Sherif N. Electrophysiologic effects of propafenone on canine ischemic cardiac cells. Am J Cardiol. 1984;54: 424-429. (Pubitemid 14055776)
29. Xu L, Jones R, Meissner G. Effects of local anesthetics on single channel behavior of skeletal muscle calcium release channel. J Gen Physiol. 1993;101:207-233. (Pubitemid 23112639)
30. Shoshan-Barmatz V, Zchut S. The interaction of local anesthetics with the ryanodine receptor of the sarcoplasmic reticulum. J Membr Biol. 1993; 133:171-181. (Pubitemid 23132065)
31. Honerjager P, Loibl E, Steidl I, Schonsteiner G, Ulm K. Negative ino-tropic effects of tetrodotoxin and seven class 1 antiarrhythmic drugs in relation to sodium channel blockade. Naunyn Schmiedebergs Arch Pharmacol. 1986;332:184-195. (Pubitemid 16134508)
32. A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias: Antiarrhythmic Drug Evaluation Group (A.D.E.G.). Eur Heart J. 1992;13:1251-1258.
33. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, Saito A, Kurosaki K, Jouo K, Koujiro M, Konishi S, Matsuoka S, Oono T, Hayakawa S, Miura M, Ushinohama H, Shibata T, Niimura I. Catecholaminergic polymorphic ventricular tachycardia: electrocardio-graphic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89:66-70. (Pubitemid 36044293)
34. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S, Belhassen B, Viskin S. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4:1149-1154. (Pubitemid 47324118)
35. Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T, Ferrandi C, Koolbergen DR, Odero A, Schwartz PJ. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008;358:2024-2029. (Pubitemid 351656456)
36. Katz G, Khoury A, Kurtzwald E, Hochauser E, Porat E, Shainberg A, Seidman JG, Seidman CE, Lorber A, Eldar M, Arad M. Optimizing CPVT therapy in calsequestrin-mutant mice. Heart Rhythm. 2010;7:1676-1682.
37. Knollmann BC. Power and pitfalls of using transgenic mice to optimize therapy for CPVT: a need for randomized placebo-controlled clinical trials in genetic arrhythmia disorders (editorial). Heart Rhythm. 2010;7: 1683-1685.
38. Kang G, Giovannone SF, Liu N, Liu FY, Zhang J, Priori SG, Fishman GI. Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy. Circ Res. 107:512-519.
39. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
40. Kroemer HK, Fromm MF, Buhl K, Terefe H, Blaschke G, Eichelbaum M. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation. 1994;89:2396-2400. (Pubitemid 24142822)
41. Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJ, Eichelbaum M, Woosley RL, Roden DM. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation. 1989;79:1068-1076. (Pubitemid 19129189)